Interleukin Genetics, Inc. (OTCQB: ILIU) today issued financial and operational results for the third quarter ended September 30, 2013.
“During the first nine months of 2013, we made significant progress toward commercialization of our PST® test, a transformative genetic test that predicts a patient’s risk for periodontal disease progression and therefore their need for different levels of preventive care,” said Dr. Kenneth Kornman, Chief Executive Officer of Interleukin Genetics.
Help employers find you! Check out all the jobs and post your resume.
